Rockwell Medical Inc

Rockwell Medical Inc(RMTI)の株式分析

$8.170

+0.443 (+5.42%)終値時点

Loading chart…
High
8.270
Open
7.830
VWAP
8.05
Vol
36.44K
Mkt Cap
53.36M
Low
7.700
Amount
293.20K
EV/EBITDA, TTM
-13.43

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

AI analysis of Rockwell Medical Inc (RMTI)

buy

Rockwell Medical Inc (RMTI) is a good buy right now due to its current price of $8.17, which is significantly below the analyst price target of $20, indicating a potential upside of over 145%. Additionally, the RSI is at 69.278, suggesting strong momentum, while the stock has shown a 20-day change of +13.63%, indicating positive short-term performance. However, the main risk is the forward P/E ratio of 59.17, which reflects high expectations for future earnings that may not materialize.

Analyst Ratings (3)

-54.10% downside
Buy
1 Buy
1 Hold
1 Sell
Current: 8.17
安値
2.50
平均
3.75
高値
5.00

H.C. Wainwright

2026-07-09

目標株価

$20

Buy

H.C. Wainwright

2026-03-30

目標株価

$2

Buy

Maxim

2026-03-27

目標株価

$4

Buy

H.C. Wainwright

2025-11-13

目標株価

$3

Buy

HC Wainwright & Co.

2025-03-24

目標株価

$3

Strong Buy

バリュエーション指標

The current forward P/E ratio for Rockwell Medical Inc (RMTI) is 59.17, compared to its 5-year average forward P/E of 8.05.

Forward P/E

Fair
5Y Average P/E
8.05
Current P/E
59.17
割高
74.29
割安
-58.20

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-1720.18
Current EV/EBITDA
-13.43
割高
6399.47
割安
-9839.84

Forward P/S

Fair
5Y Average P/S
0.52
Current P/S
0.40
割高
0.75
割安
0.28

イベントタイムライン

2026-08-13 (ET)

06:30:00

Company Reports Q2 Revenue of $17.8M

2026-06-30 (ET)

20:00:00

Rockwell Medical Trading Halted, News Pending

2026-06-29 (ET)

06:30:00

Rockwell Medical Announces 1-for-10 Reverse Split

2026-05-20 (ET)

06:20:00

Rockwell Medical Extends Product Purchase Agreement with aQua Dialysis

2026-05-14 (ET)

06:10:00

Rockwell Medical Enters Three-Year Product Purchase Agreement with Heritage Dialysis

ニュース

RMTI FAQ — answered by Alphio AI

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rockwell Medical Inc (RMTI) is a good buy right now due to its current price of $8.17, which is significantly below the analyst price target of $20, indicating a potential upside of over 145%. Additionally, the RSI is at 69.278, suggesting strong momentum, while the stock has shown a 20-day change of +13.63%, indicating positive short-term performance. However, the main risk is the forward P/E ratio of 59.17, which reflects high expectations for future earnings that may not materialize.

3 analysts cover RMTI: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 3.75.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める